Etripamil

Drug Profile

Etripamil

Alternative Names: (-)-MSP-2017; MSP-2017; MSP-2017A; MSP-2017B

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Milestone Pharmaceuticals
  • Class Antiarrhythmics; Benzoates; Esters; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal supraventricular tachycardia
  • Preclinical Angina pectoris

Most Recent Events

  • 01 Dec 2016 Milestone Pharmaceuticals completes a phase II trial in Paroxysmal supraventricular tachycardia (In the elderly, In adults) in USA and Canada (Intranasal) (NCT02296190)
  • 12 Jan 2015 Milestone Pharmaceuticals receives IND clearance from US FDA for conducting a phase II trial in Paroxysomal supraventricular tachycardia
  • 01 Jan 2015 Phase-II clinical trials in Paroxysmal supraventricular tachycardia (In the elderly, In adults) in Canada (Intranasal) (NCT02296190) after January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top